Neurobiology of Aging
Volume 30, Issue 11 , Pages 1818-1824 , November 2009

Blood–brain barrier P-glycoprotein function decreases in specific brain regions with aging: A possible role in progressive neurodegeneration

  • Anna L. Bartels

      Affiliations

    • Department of Neurology, University Medical Centre Groningen, University of Groningen, Hanzeplein 1, 9700 RB Groningen, The Netherlands
    • Corresponding Author InformationCorresponding author. Tel.: +31 50 3612433; fax: +31 50 3611707.
    • ,
  • Rudie Kortekaas

      Affiliations

    • Department of Anatomy, University Medical Centre Groningen, University of Groningen, Hanzeplein 1, 9700 RB Groningen, The Netherlands
    • ,
  • Joost Bart

      Affiliations

    • Department of Pathology, University Medical Centre Groningen, University of Groningen, Hanzeplein 1, 9700 RB Groningen, The Netherlands
    • ,
  • Antoon T.M. Willemsen

      Affiliations

    • Department of Nuclear Medicine and Molecular Imaging, University Medical Centre Groningen, University of Groningen, Hanzeplein 1, 9700 RB Groningen, The Netherlands
    • ,
  • Onno L. de Klerk

      Affiliations

    • Department of Psychiatry, University Medical Centre Groningen, University of Groningen, Hanzeplein 1, 9700 RB Groningen, The Netherlands
    • ,
  • Jeroen J. de Vries

      Affiliations

    • Department of Neurology, University Medical Centre Groningen, University of Groningen, Hanzeplein 1, 9700 RB Groningen, The Netherlands
    • ,
  • Joost C.H. van Oostrom

      Affiliations

    • Department of Neurology, University Medical Centre Groningen, University of Groningen, Hanzeplein 1, 9700 RB Groningen, The Netherlands
    • ,
  • Klaus L. Leenders

      Affiliations

    • Department of Neurology, University Medical Centre Groningen, University of Groningen, Hanzeplein 1, 9700 RB Groningen, The Netherlands

Received 6 September 2007 ,Revised 11 January 2008 ,Accepted 5 February 2008.

References 

  1. Bart J, Willemsen ATM, Groen HJM, Van der Graaf WTA, Wegman TD, Vaalburg W, et al. Quantitative assessment of P-glycoprotein function in the rat blood–brain barrier by distribution volume of [C-11]verapamil measured with PET. Neuroimage. 2003;20(3):1775–1782
  2. Chen XH, Siman R, Iwata A, Meaney DF, Trojanowski JQ, Smith DH. Long-term accumulation of amyloid-beta, beta-secretase, presenilin-1, and caspase-3 in damaged axons following brain trauma. Am. J. Pathol. 2004;165(2):357–371
  3. Cirrito JR, Deane R, Fagan AM, Spinner ML, Parsadanian M, Finn MB, et al. P-glycoprotein deficiency at the blood–brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. J. Clin. Invest. 2005;115(11):3285–3290
  4. de Lange ECM. Potential role of ABC transporters as a detoxification system at the blood-CSF barrier. Adv. Drug Deliv. Rev. 2004;56(12):1793–1809
  5. Demeule M, Labelle M, Regina A, Berthelet F, Beliveau R. Isolation of endothelial cells from brain, lung, and kidney: expression of the multidrug resistance P-glycoprotein isoforms. Biochem. Biophys. Res. Commun. 2001;281(3):827–834
  6. Di Monte DA. The environment and Parkinson's disease: is the nigrostriatal system preferentially targeted by neurotoxins?. Lancet Neurol. 2003;2(9):531–538
  7. Drozdzik M, Bialecka M, Mysliwiec K, Honczarenko K, Stankiewicz J, Sych Z. Polymorphism in the P-glycoprotein drug transporter MDR1 gene: a possible link between environmental and genetic factors in Parkinson's disease. Pharmacogenetics. 2003;13(5):259–263
  8. Fodero-Tavoletti MT, Smith DP, McLean CA, Adlard PA, Barnham KJ, Foster LE, et al. In vitro characterization of Pittsburgh compound-B binding to Lewy bodies. J. Neurosci. 2007;27(39):10365–10371
  9. Friston KJ, Frith CD, Liddle PF, Frackowiak RSJ. Comparing functional (Pet) image––the assessment of significant change. J. Cereb. Blood Flow Metab. 1991;11(4):690–699
  10. Furuno T, Landi MT, Ceroni M, Caporaso N, Bernucci I, Nappi G, et al. Expression polymorphism of the blood–brain barrier component P-glycoprotein (MDR1) in relation to Parkinson's disease. Pharmacogenetics. 2002;12(7):529–534
  11. Graff CL, Pollack GM. Functional evidence for P-glycoprotein at the nose-brain barrier. Pharm. Res. 2005;22(1):86–93
  12. Han X, Holtzman M, McKeel DW, Kelley J, Morris JC. Substantial sulfatide deficiency and ceramide elevation in very early Alzheimer's disease: potential role in disease pathogenesis. J. Neurochem. 2002;82(4):809–818
  13. Hendrikse NH, Bart J, De Vries EGE, Groen HJM, Van der Graaf WTA, Vaalburg W. P-glycoprotein at the blood–brain barrier and analysis of drug transport with positron-emission tomography. J. Clin. Pharmacol. 2001;48S–54S
  14. Hendrikse NH, De Vries EGE, Eriks-Fluks L, Van der Graaf WTA, Hospers GAP, Willemsen ATM, et al. A new in vivo method to study P-glycoprotein transport in tumors and the blood–brain barrier. Cancer Res. 1999;59(10):2411–2416
  15. Higgins CF. Abc transporters––from microorganisms to man. Annu. Rev. Cell Biol. 1992;8:67–113
  16. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo.. Proc. Natl. Acad. Sci. U.S.A. 2000;97(7):3473–3478
  17. Kandimalla KK, Donovan MD. Localization and differential activity of P-glycoprotein in the bovine olfactory and nasal respiratory mucosae. Pharm. Res. 2005;22(7):1121–1128
  18. Kim RB. Drugs as P-glycoprotein substrates, inhibitors, and inducers. Drug Metab. Rev. 2002;34(1–2):47–54
  19. Kortekaas R, Leenders KL, van Oostrom JCH, Vaalburg W, Bart J, Willemsen ATM, et al. Blood–brain barrier dysfunction in Parkinsonian midbrain in vivo. Ann. Neurol. 2005;57(2):176–179
  20. Lee JM, Markus HS. Does the white matter in Alzheimer disease and cerebral amyloid angiopathy?. Neurology. 2006;66(1):6–7
  21. Leslie EM, Deeley RG, Cole SP. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol. Appl. Pharmacol. 2005;204(3):216–237
  22. Lockhart A, Lamb JR, Osredkar T, Sue LI, Joyce JN, Ye L, et al. PIB is a non-specific imaging marker of amyloid-beta (Abeta) peptide-related cerebral amyloidosis. Brain. 2007;130(Pt 10):2607–2615
  23. Logan J. Graphical analysis of PET data applied to reversible and irreversible tracers. Nucl. Med. Biol. 2000;27(7):661–670
  24. Mangoni AA. The impact of advancing age on P-glycoprotein expression and activity: current knowledge and future directions. Expert Opin. Drug Metab. Toxicol. 2007;3(3):315–320
  25. Matsuoka Y, Okazaki M, Kitamura Y, Taniguchi T. Developmental expression of P-glycoprotein (multidrug resistance gene product) in the rat brain. J. Neurobiol. 1999;39(3):383–392
  26. Mooradian AD. Effect of aging on the blood–brain barrier. Neurobiol. Aging. 1988;9(1):31–39
  27. Morita N, Yasumori T, Nakayama K. Human MDR1 polymorphism: G2677T/A and C3435T have no effect on MDR1 transport activities. Biochem. Pharmacol. 2003;65(11):1843–1852
  28. Pfefferbaum A, Adalsteinsson E, Sullivan EV. Frontal circuitry degradation marks healthy adult aging: evidence from diffusion tensor imaging. Neuroimage. 2005;26(3):891–899
  29. Roher AE, Kuo YM, Esh C, Knebel C, Weiss N, Kalback W, et al. Cortical and leptomeningeal cerebrovascular amyloid and white matter pathology in Alzheimer's disease. Mol. Med. 2003;9(3–4):112–122
  30. Rosati A, Maniori S, Decorti G, Candussio L, Giraldi T, Bartoli F. Physiological regulation of P-glycoprotein, MRP1, MRP2 and cytochrome P450 3A2 during rat ontogeny. Dev. Growth Differ. 2003;45(4):377–387
  31. Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, Savage G, et al. Imaging beta-amyloid burden in aging and dementia. Neurology. 2007;68(20):1718–1725
  32. Saito Y, Kawashima A, Ruberu NN, Fujiwara H, Koyama S, Sawabe M, et al. Accumulation of phosphorylated alpha-synuclein in aging human brain. J. Neuropathol. Exp. Neurol. 2003;62(6):644–654
  33. Salat DH, Tuch DS, Greve DN, van der Kouwe AJ, Hevelone ND, Zaleta AK, et al. Age-related alterations in white matter microstructure measured by diffusion tensor imaging. Neurobiol. Aging. 2005;26(8):1215–1227
  34. Schinkel AH, Smit JJM, Vantellingen O, Beijnen JH, Wagenaar E, Vandeemter L, et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood–brain-barrier and to increased sensitivity to drugs. Cell. 1994;77(4):491–502
  35. Schoenberg BS, Osuntokun BO, Adeuja AOG, Bademosi O, Nottidge V, Anderson DW, et al. Comparison of the prevalence of parkinsons-disease in black populations in the rural United-States and in rural Nigeria––door-to-door community studies. Neurology. 1988;38(4):645–646
  36. Soffer D. Cerebral amyloid angiopathy––a disease or age-related condition. Isr. Med. Assoc. J. 2006;8(11):803–806
  37. Song SK, Kim JH, Lin SJ, Brendza RP, Holtzman DM. Diffusion tensor imaging detects age-dependent white matter changes in a transgenic mouse model with amyloid deposition. Neurobiol. Dis. 2004;15(3):640–647
  38. Stewart PA, Magliocco M, Hayakawa K, Farrell CL, Del Maestro RF, Girvin J, et al. A quantitative analysis of blood–brain barrier ultrastructure in the aging human. Microvasc. Res. 1987;33(2):270–282
  39. Takano A, Kusuhara H, Suhara T, Ieiri I, Morimoto T, Lee YJ, et al. Evaluation of in vivo P-glycoprotein function at the blood–brain barrier among MDR1 gene polymorphisms by using 11C-verapamil. J. Nucl. Med. 2006;47(9):1427–1433
  40. Thiruchelvam M, Brockel BJ, Richfield EK, Baggs RB, Cory-Slechta DA. Potentiated and preferential effects of combined paraquat and maneb on nigrostriatal dopamine systems: environmental risk factors for Parkinson's disease?. Brain Res. 2000;873(2):225–234
  41. Toornvliet R, van Berckel BNM, Luurtsema G, Lubberink M, Geldof AA, Bosch TM, et al. Effect of age on functional P-glycoprotein in the blood–brain barrier measured by use of (R)-[C-11]verapamil and positron emission tomography. Clin. Pharmacol. Ther. 2006;79(6):540–548
  42. Tsai CE, Daood MJ, Lane RH, Hansen TW, Gruetzmacher EM, Watchko JF. P-glycoprotein expression in mouse brain increases with maturation. Biol. Neonate. 2002;81(1):58–64
  43. Ueno M, Akiguchi I, Hosokawa M, Kotani H, Kanenishi K, Sakamoto H. Blood–brain barrier permeability in the periventricular areas of the normal mouse brain. Acta Neuropathol. (Berl.). 2000;99(4):385–392
  44. Vogelgesang S, Cascorbi I, Kroemer HK, Schroeder E, Pahnke J, Siegmund W, et al. Deposition of amyloid is inversely correlated with the expression of p-glycoprotein––implications on the possibility of prevention of Alzheimer's disease. Acta Neuropathol. 2001;102(5):545
  45. Vogelgesang S, Cascorbi I, Schroeder E, Pahnke J, Kroemer HK, Siegmund W, et al. Deposition of Alzheimer's beta-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans. Pharmacogenetics. 2002;12(7):535–541
  46. Vogelgesang S, Glatzel M, Walker LC, Kroemer HK, Aguzzi A, Warzok RW. Cerebrovascular P-glycoprotein expression is decreased in Creutzfeldt–Jakob disease. Acta Neuropathol. (Berl). 2006;111(5):436–443
  47. Vogelgesang S, Kuhnke D, Jedlitschky G, Jucker M, Mosyagin I, Pahnke J, et al. P-glycoprotein (ABCB1) mediates transport of Alzheimer's beta-amyloid peptides. Acta Neuropathol. 2006;112(3):365–367
  48. Wegman TD, Maas B, Elsinga PH, Vaalburg W. An improved method for the preparation of [C-11]verapamil. Appl. Radiat. Isot. 2002;57(4):505–507
  49. Yokel RA. Blood–brain barrier flux of aluminum, manganese, iron and other metals suspected to contribute to metal-induced neurodegeneration. J. Alzheimers Dis. 2006;10(2–3):223–253

PII: S0197-4580(08)00042-0

doi: 10.1016/j.neurobiolaging.2008.02.002

Neurobiology of Aging
Volume 30, Issue 11 , Pages 1818-1824 , November 2009

Article Tools

* Image Usage & Resolution